Elbasvir And Grazoprevir has 25 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 5 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Efavirenz, Grazoprevir, Amlodipine And Atorvastatin. Patients taking Elbasvir And Grazoprevir should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 25
- Contraindicated
- 2
- Major
- 5
- Moderate
- 2
Contraindicated (2)
- Elbasvir And Grazoprevir + Efavirenz— Co-administration with efavirenz is contraindicated as it is a strong CYP3A inducer that may decrease elbasvir and grazo…
- Elbasvir And Grazoprevir + Grazoprevir— ( 4 , 5.5 , 7 , 12.3 ) 7.1 Potential for Drug Interactions Grazoprevir is a substrate of OATP1B1/3 transporters. Co-admi…
Major (5)
- Elbasvir And Grazoprevir + Amlodipine And Atorvastatin— Do not exceed 20 mg atorvastatin daily due to increased risk of myopathy and rhabdomyolysis.
- Elbasvir And Grazoprevir + Atorvaliq— Significantly increases atorvastatin plasma levels. Do not exceed ATORVALIQ 20 mg.
- Elbasvir And Grazoprevir + Atorvastatin Calcium— Significantly increases atorvastatin plasma levels. Do not exceed atorvastatin 20 mg.
- Elbasvir And Grazoprevir + Rosuvastatin— Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.
- Elbasvir And Grazoprevir + Rosuvastatin Calcium— Increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.
Moderate (2)
- Elbasvir And Grazoprevir + Elbasvir— Elbasvir and grazoprevir are substrates of CYP3A and P-gp, but the role of intestinal P-gp in the absorption of elbasvir…
- Elbasvir And Grazoprevir + Warfarin— Clearance of HCV infection may lead to changes in hepatic function affecting warfarin metabolism. Frequent monitoring of…